EPRX — Eupraxia Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$191.44m
- CA$187.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 81.3 | ||
| Price to Tang. Book | 81.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.81% | ||
| Return on Equity | -1302.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 16.47 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 11th, 2012
- Public Since
- March 9th, 2021
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 35,849,353
- Address
- 201-2067 Cadboro Bay Rd., VICTORIA, V8R 5G4
- Web
- https://eupraxiapharma.com/home/default.aspx
- Phone
- +1 2505903968
- Contact
- Aadam Peeler
- Auditors
- KPMG LLP
Upcoming Events for EPRX
Similar to EPRX
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
FAQ
What is the Eupraxia Pharmaceuticals share price?
As of Today at 20:30 UTC, shares in Eupraxia Pharmaceuticals are trading at CA$5.34. This share price information is delayed by 15 minutes.
How has the Eupraxia Pharmaceuticals share price performed this year?
Shares in Eupraxia Pharmaceuticals last closed at CA$5.34 and the price had moved by +36.92% over the past 365 days. In terms of relative price strength the Eupraxia Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +21.73% over the past year.
What are the analyst and broker recommendations for Eupraxia Pharmaceuticals?
The overall consensus recommendation for Eupraxia Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eupraxia Pharmaceuticals dividend yield?
Eupraxia Pharmaceuticals does not currently pay a dividend.
Does Eupraxia Pharmaceuticals pay a dividend?
Eupraxia Pharmaceuticals does not currently pay a dividend.
When does Eupraxia Pharmaceuticals next pay dividends?
Eupraxia Pharmaceuticals does not currently pay a dividend.
How do I buy Eupraxia Pharmaceuticals shares?
To buy shares in Eupraxia Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eupraxia Pharmaceuticals?
As of the previous close price of CA$5.34, shares in Eupraxia Pharmaceuticals had a market capitalisation of CA$191.44m.
Where are Eupraxia Pharmaceuticals shares listed?
Here are the trading details for Eupraxia Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: EPRX
What kind of share is Eupraxia Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eupraxia Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eupraxia Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Eupraxia Pharmaceuticals is CA$10.13. That is 89.7% above the last closing price of CA$5.34.
Analysts covering Eupraxia Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.67 for the next financial year.
Find out moreWhat is the trend in the Eupraxia Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eupraxia Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +54.77%.
As of the last closing price of CA$5.34, shares in Eupraxia Pharmaceuticals were trading +25.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eupraxia Pharmaceuticals PE Ratio?
The Eupraxia Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$5.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eupraxia Pharmaceuticals?
We do not have data on Eupraxia Pharmaceuticals' directors